Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

Completed · Phase 1

Conditions studied: Inflammation

In brief

Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

Key facts

Study ID

NCT01164085

Run by

Vanderbilt University

People needed

10

Starts

2009-12-01

Expected to finish

2010-12-01

Last updated by the study team

2013-12-31

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult volunteers
• Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment
• Unable to tolerate corticosteroids due to side effects

You may not qualify if…

• 18 years or younger
• Have active ocular infection
• Pregnancy

Where it is running

• Vanderbilt Eye Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.